| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2002;40:342.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
From the Hypertension and Stroke Research Laboratories, Department of Physiology, University of Sydney, and Department of Neurosurgery, Royal North Shore Hospital, Sydney, Australia.
Correspondence to Associate Professor Paul M. Pilowsky, Hypertension and Stroke Research Laboratories, Ground Floor, Block 3, Royal North Shore Hospital, Sydney, 2065, Australia. E-mail pilowsky{at}med.usyd.edu.au
| Abstract |
|---|
|
|
|---|
1A-receptor (
1A-R), and
2A-receptor (
2A-R) vary with resting systolic blood pressure in spontaneously hypertensive rats (SHR) compared with normotensive Wistar-Kyoto (WKY) or Sprague-Dawley (SD) rats. Sites examined included central and peripheral regions associated with the control of arterial pressure. Twenty week old SD (n=6), WKY (n=6), and SHR (n=6) were used. Systolic blood pressure was measured using tail cuff plethysmography 2 weeks before tissue extraction. RNA was isolated and reverse-transcribed into cDNA. Gene expression levels were measured, using quantitative real time PCR, relative to the expression of GAPDH. PNMT, NAT, and
1A-R mRNA expression was significantly greater in SHR tissue samples compared with normotensives. In the rostral ventrolateral medulla, PNMT mRNA in SHR was 3 times greater than that in WKY (SHR: 0.82±0.02%; WKY: 0.29±0.02%). The amount of
2A-R mRNA was significantly lower in SHR compared with normotensives. For example, the level of
2A-R mRNA in spinal cord of SHR was 3 times less than that found in WKY (SHR: 1.85±0.04%; WKY: 3.26±0.07%). PNMT, NAT, and
1A-R mRNA levels were positively correlated with systolic blood pressure in all central tissue investigated. Conversely,
2A-R mRNA levels in central sites were negatively correlated with systolic blood pressure. Clearly, a decrease in central
2A-R and an increase in
1A-R is consistent with the elevated blood pressure and sympathetic activity observed in SHR.
Key Words: catecholamines hypertension, genetic receptors, adrenergic alpha renin-angiotensin system sympathetic nervous system
| Introduction |
|---|
|
|
|---|
Both noradrenaline and adrenaline act at G protein-coupled receptors of the adrenergic receptor family, comprising
1,
2, or ß, to mediate sympathetic effects.7 Within this main classification, there are several subtypes
1A,
1B,
1D,
2A,
2B,
2C, ß1, ß2, and ß3. In this study we focus on 2 of these receptors,
1A-R and
2A-R. Both of these receptor subtypes have been strongly implicated in cardiovascular control. Activation of the
1A-R subtype causes mobilization of Ca2+ influx and production of gene transcription factors, such as Fos.7 The
1A-R is found in peripheral tissue such as the heart and kidneys, as well as in central tissue.7 Presynaptic
2A-R activation closes voltage-gated Ca2+ channels and opens K+ channels.7 The
2A-R displays high immunoreactivity in the spinal cord and lower brain stem and is also expressed in some peripheral tissues, but in lower amounts.7 Catabolism and reuptake of noradrenaline within the synaptic cleft is achieved either by the actions of the catabolic enzymes catechol-O-methyltransferase8 and monoamine oxidase8 or by the noradrenaline transporter (NAT), which has been localized to regions of the pons and medulla oblongata.9 The aims of this study were, first, to measure the levels in expression of the genes for PNMT, NAT,
1A-R, and
2A-R in hypertensive rats and compare them with normotensive rats at central and peripheral tissue sites that are involved in the sympathetic control of arterial blood pressure. Secondly, our aim was to determine if any relationship exists between levels of gene expression and systolic blood pressure (SBP).
| Methods |
|---|
|
|
|---|
|
RNA Isolation and Quantitative Real Time RT-PCR
Total RNA was isolated according to a protocol previously described by Reja et al.1 Briefly, an equal amount of each RNA sample, totalling approximately 100 ng, was reverse transcribed into complementary DNA (cDNA) using the Reverse Transcriptase System (Promega) according to the manufacturers protocol. Relative quantitative PCR was achieved using the fluorogenic intercalating dye SYBRGreen and previously published primers to the genes for NAT,9 PNMT,11
1A-R,12 and
2A-R.12 Each 20-µL reaction contained 2.5 mmol/L MgCl2, 1x PCR buffer, 0.25 µmol/L each primer, 0.3x SYBRGreen (1:106 working stock, Molecular Probes), 0.625 U Taq polymerase (Promega), and template cDNA. Amplification was performed in 0.2 mL tubes on a Rotor Gene 2000 Real Time PCR Machine (Corbett Research). PCR parameters were an initial denature at 94°C for 180 seconds followed by 35 cycles of 94°C for 15 seconds, 60 to 65°C (depending on primer: GAPDH 65°C; NAT 60°C; PNMT 60°C;
1A-R 60°C;
2A-R 65°C) for 20 seconds, and 72°C for 25 sec. Fluorescence data were acquired at the end of extension. A melt analysis was run for all products to determine the specific amplification. In addition, PCR products were run on 2% tri-borate ethylenediaminetetraacetic acid (TBE) agarose gels to confirm that correct band sizes were present (Figure 1D). A standard curve was generated by amplifying, in serially diluted cDNA samples, the endogenous cDNA standard GAPDH using published primer sequences.11 Although it has been reported that under extreme experimental conditions the levels of GAPDH change,13 it has been demonstrated by our laboratory that the levels of GAPDH do not vary between WKY and SHR (Figure 1C). This was achieved by serially diluting (1:1, 1:10, and 1:100) cDNA from WKY and SHR in equal amounts, amplifying the GAPDH gene, and then comparing the Ct values (cycle threshold set where the exponential phase of the PCR reaction began) obtained for each strain. Equal Ct values indicated that the levels of GAPDH did not vary between strains. By plotting the Ct values for GAPDH (y) against the concentration of cDNA (x), a standard curve was generated from which the unknown amount of each gene expressed within the sample was determined.
Data Analysis
Data were normalized and all values are expressed as amount of target as a percentage of GAPDH cDNA in the sample ±SEM for each strain of animal. An unpaired Student t test was used to determine if there were any significant differences between groups (
=0.05). To determine the relationship between systolic blood pressure and the relative amount of target gene, a correlation coefficient was determined in all strains for all tissues and targets. Regression curves were plotted for WKY (n=6) and SHR (n=6) using the systolic blood pressure of each animal against the level of gene expression for each animal.
| Results |
|---|
|
|
|---|
1A-R fragment (250 bp), and
2A-R fragment (337 bp) (Figure 1D). There were no nonspecific products observed in any of the samples and no genomic DNA amplification in RT negative controls (Figure 1D), which was further confirmed by a melt analysis of each product (data not shown).
Measurement of PNMT, NAT,
1A-R, and
2A-R cDNA within the 6 sites examined gave the results shown in Figures 2A through 2F. The first 3 sites examined were from central tissue known to be involved in the regulation of arterial blood pressure: the VMH, RVLM, and spinal cord. Figure 2A shows the data obtained from the VMH. No PNMT cDNA was found in any species within any of the VMH tissue samples. VMH tissue taken from SHR showed a significant increase in the amount of NAT and
1A-R cDNA compared with that taken from SD or WKY by a ratio of 7:1 and 2:1, respectively (NAT: SHR=0.034±0.003% [n=6], WKY= 0.004±0.0001% [n=6], P<0.0001;
1A-R: SHR=3.26±0.04% [n=6], WKY=1.42±0.07% [n=6], SD=1.46±0.05% [n=6], P<0.0001). However, the amount of
2A-R cDNA taken from SHR was significantly less than that found in SD or WKY by a ratio of 1:4 (
2A-R: SHR=1.35±0.05% [n=6], WKY=4.91±0.17% [n=6], SD=4.57±0.12% [n=6], P<0.0001). The second central site examined was the RVLM (Figure 2B). RVLM tissue punches taken from SHR demonstrated significant increases in PNMT, NAT, and
1A-R cDNA compared with that of SD or WKY by ratios of 3:1, 2:1, and 2:1, respectively (PNMT: SHR=0.82± 0.02% [n=6], WKY=0.29±0.02% [n=6], SD=0.31±0.01% [n=6], P<0.0001; NAT: SHR=0.78±0.02% [n=6], WKY= 0.37±0.01% [n=6], SD=0.31±0.02% [n=6], P<0.0001;
1A-R: SHR=4.10±0.11% [n=6], WKY=2.95±0.15% [n=6], SD= 2.52±0.10% [n=6], P<0.01). As observed in VMH tissue samples, the amount of
2A-R cDNA in RVLM tissue samples taken from SHR was significantly less than that in SD or WKY by a ratio of 1:3 (
2A-R: SHR=1.38±0.04% [n=6], WKY=4.19±0.19% [n=6], SD=3.77±0.18% [n=6], P<0.0001). The final central site studied was the thoracic spinal cord (Figure 2C). There was no amplification of PNMT or NAT cDNA in any of the spinal cord tissue samples. Like the VMH and RVLM, the amount of
1A-R found in spinal cord tissue taken from SHR was significantly greater than in that from SD or WKY by a ratio of 2:1 (
1A-R: SHR=5.73±0.11% [n=6], WKY=2.63±0.05% [n=6], SD=2.46±0.08% [n=6], P<0.001). Similarly, the amount of
2A-R cDNA was significantly lower in spinal cord tissue taken from SHR compared with that from SD or WKY by a ratio of 2:3 (
2A-R: SHR=1.85±0.04% [n=6], WKY=3.26±0.07% [n=6], SD=2.98±0.11% [n=6], P<0.001). A consistent pattern was observed in central tissue when the amount of
2A-R and
1A-R was investigated in normotensive and hypertensive animals. In normotensive animals the amount of
2A-R cDNA detected was significantly greater than the amount of
1A-R cDNA (P<0.001, n=6 in each group). In contrast, in the SHR the amount of
2A-R cDNA detected was significantly less than the amount of
1A-R cDNA (P<0.001, n=6 in each group).
|
Three peripheral sites were also investigated: the renal medulla, the heart, and the adrenal medulla. Results for tissue biopsies obtained from the renal medulla are shown in Figure 2D. There was no positive amplification of PNMT or NAT cDNA in any of the renal medullary tissue samples. Interestingly, tissue obtained from the renal medulla of SHR showed a significantly lower amount of
1A-R cDNA along with
2A-R cDNA compared with that from SD or WKY by ratios of 1:3 and 2:3, respectively (
1A-R: SHR=1.94±0.06% [n=6], WKY=4.86±0.19% [n=6], SD=5.51±0.15% [n=6], P<0.0001;
2A-R: SHR=1.11±0.04% [n=6], WKY=1.77±0.06% [n=6], SD=1.96±0.11% [n=6], P<0.001). Only
1A-R and
2A-R cDNA could be amplified from the myocardium (Figure 2E). The amount of
1A-R cDNA detected in tissue taken from the myocardium of SHR was significantly greater than that from SD or WKY by a ratio of 2:1 (
1A-R: SHR=7.13±0.13% [n=6], WKY=5.00±0.22% [n=6], SD=5.37±0.15% [n=6], P<0.0001). The amount of
2A-R cDNA detected in myocardial tissue taken from SHR was significantly lower than that detected in SD or WKY by a ratio of 2:5 (
2A-R: SHR=0.14±0.01% [n=6], WKY=0.35±0.02% [n=6], SD=0.34±0.02% [n=6], P<0.001). Finally, we detected and measured the levels of PNMT, NAT,
1A-R, and
2A-R cDNA in adrenal medulla tissue (Figure 2F). In the adrenal medulla, the amount of PNMT, NAT, and
1A-R cDNA taken from SHR was significantly greater than in SD or WKY by a ratio of 1.5:1, 3:1, and 3:1, respectively (PNMT: SHR=7.59±0.09% [n=6], WKY= 6.40±0.11% [n=6], SD=6.57±0.15% [n=6], P<0.01); NAT: SHR=3.97±0.10% [n=6], WKY=1.30±0.04% [n=6], SD=1.29±0.03% [n=6], P<0.0001;
1A-R: SHR=7.47±0.17% [n=6], WKY=2.76±0.15% [n=6], SD=3.45±0.10% [n=6], P<0.0001). The amount of
2A-R cDNA in adrenal medulla taken from SHR was significantly lower than that from SD or WKY by a ratio of 2:3 (
2A-R: SHR=0.64±0.02% [n=6], WKY=0.95± 0.03% [n=6], SD=0.94±0.03% [n=6], P<0.001). Thus, similarly to the central pattern, peripheral tissue of SHR consistently showed
2A-R was less then
1A-R. In contrast, unlike the central tissue, the amount of
1A-R cDNA detected in peripheral tissue was significantly higher than the amount of
2A-R cDNA in normotensive and hypertensive strains (P<0.001).
The relationship between systolic blood pressure and the level of gene expression in all strains and for all tissues was investigated. No significant correlation was observed in any of the normotensive tissue samples for any of the targets. In the SHR, however, there were significant correlations observed between SBP and the level of gene expression in a number, but not all, of the tissues (Figures 3A through 3L). Within the VMH there was a positive and significant correlation between the amounts of NAT cDNA (r2=0.93, P<0.05, n=6, Figure 3A) and
1A-R cDNA (r2=0.86, P<0.05, n=6, Figure 3B), and SBP. The amount of
2A-R cDNA in VMH tissue was significantly and negatively correlated to SBP (r2=-0.82, P<0.05, n=6, Figure 3C). RVLM tissue showed a positive and significant correlation between the amounts of PNMT (r2=0.91, P<0.05, n=6, Figure 3D), NAT (r2=0.91, P<0.05, n=6, Figure 3E), and
1A-R (r2=0.97, P<0.001, n=6, Figure 3F) cDNA and SBP. The amount of
2A-R cDNA in RVLM tissue punches was significantly and negatively correlated to SBP (r2=-0.87, P<0.05, n=6, Figure 3G). In the spinal cord, the amount of
1A-R cDNA was significantly and positively correlated to SBP (r2=0.97, P<0.001, n=6, Figure 3H). Interestingly, in tissue taken from the renal medulla of SHR, the amount of
1A-R cDNA was significantly and negatively correlated to SBP (r2=-0.89, P<0.05, n=6, Figure 3I). Myocardial tissue taken from SHR showed a positive and significant correlation between the amount of
1A-R cDNA and SBP (r2=0.98, P<0.001, n=6, Figure 3J). Finally, there was a significant and positive correlation between the amounts of NAT cDNA (r2=0.97, P<0.001, n=6, Figure 3K) and
1A-R cDNA (r2=0.90, P<0.05, n=6, Figure 3L), and SBP in adrenal gland tissue taken from SHR.
|
| Discussion |
|---|
|
|
|---|
1A-R were always higher, and the levels of
2A-R were always lower in all tissue samples investigated in SHR compared with both normotensive strains (except for the
1A-R in the renal medulla). Despite the exception, the data suggests that the changes in gene expression between SHR and normotensive are global rather than site-specific. The genes were expressed at sites previously identified to contain cells that express the gene or its protein product. PNMT was expressed in RVLM punches11 and adrenal medullary tissue.14 Both adrenergic receptors were expressed in all tissue investigated.7 NAT was expressed in hypothalamus, 15 RVLM,9 and adrenal medulla.16 In this study we have demonstrated for the first time that the levels of gene expression of PNMT, NAT,
1A-R, and
2A-R within central tissue samples taken from SHR, but not so in SD or WKY, are significantly correlated to SBP, except for the
2A-R in the spinal cord. The range of SHR SBP was fortuitous in this randomly selected cohort. This contrasts with peripheral tissue where only 4 correlations out of a possible 8 were significant. The lack of any significant correlation between the expression of targeted genes and SBP in WKY or SD could be due to the small range in SBPs observed for each strain (eg, 101 to 105 mm Hg for WKY). Therefore, it is still conceivable that, although no correlation was observed for the group data of SD or WKY, a small relationship might be uncovered if a larger population were to be investigated. The VMH, RVLM, and intermediolateral cell column of the spinal cord all play important roles in cardiovascular control and represent second- and third-order neurons and presympathetic and sympathetic neurons, respectively. The results suggest that, within central tissue sites related to cardiovascular control, there appears to be a strong relationship between the levels of each catecholaminergic-related gene transcribed and SBP. In this study we have found a significant increase in PNMT and NAT mRNA levels in the RVLM of SHR compared with WKY. Previously we demonstrated a similar finding for TH.1 Furthermore, the level of 3 genes whose products are involved in the synthesis or uptake of catecholamines in the RVLM were significantly and positively correlated to SBP. NAT neurons found in the RVLM comprise a small minority of C1 cells. Although Lorang et al, 16 using hybridization histochemistry, suggest that NAT is not expressed in C1 neurons, Comer et al,9 using carefully devised single-cell PCR studies, found that NAT was expressed in 10% of identified bulbospinal C1 neurons. In the present study, it is still possible that some of the NAT gene expression within the RVLM originated from stray A1 neurons. Angiotensin II induces higher levels of NAT mRNA in SHR than in WKY17 and causes an increase in MAP when injected into the RVLM.18 Consistent with this observation, we find an increase in NAT in SHR compared with WKY. Increases in TH,1 PNMT, and NAT mRNA suggest a heightened activation of the adrenergic system in SHR RVLM, with increased production of noradrenaline and adrenaline, along with an increased reuptake of catecholamines from the synaptic cleft. That this is a global upregulation of catecholamine synthesis and uptake is supported by similar findings from the VMH (NAT) and the adrenal medulla (NAT and PNMT).
1A-R and
2A-R are 2 of a family of receptors that are responsible for mediating the effects of noradrenaline and adrenaline. They are both strongly implicated in the control of arterial pressure although other subtypes may also play a role as evidenced from experiments in transgenic animals.19
2-R agonists cause a centrally mediated hypotension and bradycardia via
2A-R and peripherally derived hypertension via
2B-R.19
2A-R knockout mice have increased heart rates and blood pressure as well as elevated plasma catecholamines.20
2A-Rs are also found at select peripheral locations and are commonly presynaptic.7
1A-Rs found in central tissue are generally postsynaptic and thought to be stimulatory in nature. They also play a dominant role in the periphery where they regulate contraction of smooth muscle associated with particular vessels, particularly the renal arteries.7 In support of this,
1A-R knockout mice show a decrease in mean arterial pressure and a decreased response to the
1A-R agonist, phenylephrine.21 Here we find in SHR that the amount of
1A-R is significantly greater, whereas the amount of
2A-R gene expression is significantly lower compared with normotensive rats in all tissue except the renal medulla. These results strongly support the observations of Tavares et al22 who demonstrated, using in situ hybridization (ISH), 20% less
2A-R within the pons-medulla of SHR compared with WKY and Bottiglieri et al23 who used ISH to demonstrate higher amounts of
1A-R gene expression in the hypothalamus and neuronal cultures of SHR, respectively. However, the key advantages to our method compared with those used by Tavares et al22 and others is that we are able to accurately measure smaller amounts of RNA and are therefore able to measure gene expression in smaller site-specific regions. The pattern of gene expression seen is evident for all related genes in central tissues associated with cardiovascular control, but particularly in the RVLM. In central tissue of normotensive animals, the
2A-R is dominant.24 Data from the present study is consistent with the idea that the level of sympathetic outflow may be due to the balance of
1A-R and
2A-R, because
1A-R are found at higher levels in SHR, and
2A-R are found at lower levels in this strain at all sites examined. This idea is supported by the observations that genetically manipulated mice that lack the
2A-R become hypertensive at a faster rate under a salt diet than that of their wild-type counterparts.20
The only tissue that stood out in our six sample sites was the renal medulla. Here the amount of
1A-R cDNA amplified in renal medulla tissue samples taken from SHR was significantly lower compared with SD or WKY. The lower levels of
1A-R gene expression observed in SHR renal medulla tissue could be due to the heterogeneity of the kidney itself. The renal medulla contains blood vessels and parts of the renal tubular system that possess specialized cells for the regulation of an osmotic gradient that is important to the kidneys ability to produce urine of various concentrations. We speculate that a decrease in
1A-R would lead to a decrease in glomerular blood pressure and therefore lead to an increased conservation of fluid and salt, causing blood pressure to rise. Alternatively, a complex change in the expression of
1A-R on different parts of the renal vasculature could account for the apparently paradoxical effects seen in this tissue.
In this study, selective regional differences were identified in the levels of gene expression between hypertensive and normotensive animals. Furthermore, in SHR there were significant correlations with SBP in some, but not all, sites examined. Whether or not these relationships are causes of, effects of, or simply incidental to, the differences in arterial blood pressure remains to be determined. We propose that basal arterial pressure levels are set predominantly by a balance of
1A-R and
2A-R activation. The SHR model has been shown to have elevated angiotensin II and a dysfunctional regulation of AT1-R by
1A-R.25 The elevated pressures could arise, therefore, from elevated levels of catecholamine biosynthesis and elevated
1A-R levels with a concomitant decrease in
2A-R regulation.
| Acknowledgments |
|---|
Received April 15, 2002; first decision May 17, 2002; accepted June 17, 2002.
| References |
|---|
|
|
|---|
2. Chalmers JP, Minson JB, Denoroy L, Stead B, Howe PR. Brainstem PNMT neurons and experimental hypertension in the rat. Clin Exp Hypertens. 1984; 6: 243258.
3. Goodchild AK, Llewellyn-Smith IJ, Sun QJ, Chalmers J, Cunningham AM, Pilowsky PM. Calbindin-immunoreactive neurons in the reticular formation of the rat brainstem: catecholamine content and spinal projections. J Comp Neurol. 2000; 424: 547562.[CrossRef][Medline] [Order article via Infotrieve]
4. Blessing WW. The Lower Brainstem and Bodily Homeostasis. New York, NY: Oxford University Press; 1997: 165268.
5. Morrison SF, Callaway J, Milner TA, Reis DJ. Rostral ventrolateral medulla: a source of the glutamatergic innervation of the sympathetic intermediolateral nucleus. Brain Res. 1991; 562: 126135.[CrossRef][Medline] [Order article via Infotrieve]
6. Roy ML, Sellers EM, Flattery KV, Sellers EA. Influence of cold exposure and thyroid hormones on regulation of adrenal catecholamines. Can J Physiol Pharmacol. 1977; 55: 804812.[Medline] [Order article via Infotrieve]
7. Civantos CB, Aleixandre AA. Alpha-adrenoceptor subtypes. Pharmacol Res. 2001; 44: 195208.[CrossRef][Medline] [Order article via Infotrieve]
8. Napolitano A, Cesura AM, Da Prada M. The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission. J Neural Transm Suppl. 1995; 45: 3545.[Medline] [Order article via Infotrieve]
9. Comer AM, Qi J, Christie DL, Gibbons HM, Lipski J. Noradrenaline transporter expression in the pons and medulla oblongata of the rat: localization to noradrenergic and some C1 adrenergic neurons. Mol Brain Res. 1998; 62: 6576.[Medline] [Order article via Infotrieve]
10. Cabassi A, Vinci S, Cantoni AM, Quartieri F, Moschini L, Cavazzini S, Cavatorta A, Borghetti A. Sympathetic activation in adipose tissue and skeletal muscle of hypertensive rats. Hypertension. 2002; 36 (suppl II): 656661.
11. Comer AM, Yip S, Lipski J. Detection of weakly expressed genes in the rostral ventrolateral medulla of the rat using micropunch and reverse transcription-polymerase chain reaction techniques. Clin Exp Pharmacol Physiol. 1997; 24: 755759.[Medline] [Order article via Infotrieve]
12. Phillips JK, Vidovic M, Hill CE. Alpha-adrenergic, neurokinin and muscarinic receptors in rat mesenteric artery; an mRNA study during postnatal development. Mech Age Develop. 1996; 92: 235246.[CrossRef]
13. Zhong H, Simons J. Direct comparison of GAPDH, b-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem Biophys Res Commun. 1999; 259: 523526.[CrossRef][Medline] [Order article via Infotrieve]
14. Morita K, Kuwanda A, Sano A, Sakata M, Sei H, Morita Y. Semi-quantitative RT-PCR analysis of environmental influence on P450scc and PNMT mRNA expression in rat adrenal glands. Life Sci. 2001; 70: 7380.[Medline] [Order article via Infotrieve]
15. Schroeter S, Apparsundaram S, Wiley RG, Miner LH, Sesack SR, Blakely RD. Immunolocalization of the cocaine- and antidepressant-sensitive 1-norepinephrine transporter. J Comp Neurol. 2000; 420: 211232.[CrossRef][Medline] [Order article via Infotrieve]
16. Lorang D, Amara SG, Simerly RB. Cell-type-specific expression of catecholamine transporters in the rat brain. J Neurosci. 1994; 14: 49034914.[Abstract]
17. Yang H, Lu D, Yu K, Raizada MK. Regulation of neuromodulatory actions of angiotensin II in the brain neurons by the Ras-dependent mitogen-activated protein kinase pathway. J Neurosci. 1996; 16: 40474058.
18. Seyedabadi M, Goodchild AK, Pilowsky PM. Differential role of kinases in brain stem of hypertensive and normotensive rats. Hypertension. 2001; 38: 10871092.
19. Kable JW, Murrin LC, Bylund B. In vivo gene modification elucidates subtype-specific functions of
2-adrenergic receptors. J Pharmacol Exp Ther. 2000; 293: 17.
20. Gavras I, Gavras H. Role of
2-adrenergic receptors in hypertension. Am J Hypertens. 2001; 14: 171S177S.[CrossRef][Medline]
[Order article via Infotrieve]
21. Piascik MT, Perez DM.
1-Adrenergic receptors: new insight and directions. J Pharmacol Exp Ther. 2001; 298: 403410.
22. Tavares A, Handy DE, Bogdanova NN, Rosene DL, Gavras H. Localization of
2A- and
2B-adrenergic receptor subtypes in brain. Hypertension. 1996; 27 (suppl I): 449455.
23. Bottiglieri DF, Morse CA, Baker SP, Crews FT, Sumners C, Raizada MK. Increased expression of alpha1-adrenergic receptors in hypothalamus of spontaneously hypertensive rat brain. Brain Res. 1988; 439: 187194.[CrossRef][Medline] [Order article via Infotrieve]
24. Hayar A, Guyenet PG.
2-Adrenoceptor-mediated presynaptic inhibition in bulbospinal neurons of rostral ventrolateral medulla. Am J Physiol. 1999; 277: H1069H1080.[Medline]
[Order article via Infotrieve]
25. Li HT, Long CS, Gray MO, Rokosh DG, Honbo NY, Karliner JS. Cross talk between AT1 and alpha 1-adrenergic receptors: angiotensin II downregulates alpha 1a-adrenergic receptor subtype mRNA and density in neonatal rat cardiac myocytes. Circ Res. 1997; 81: 396403.
This article has been cited by other articles:
![]() |
A. G. Teschemacher, S. Wang, M. K. Raizada, J. F.R. Paton, and S. Kasparov Area-Specific Differences in Transmitter Release in Central Catecholaminergic Neurons of Spontaneously Hypertensive Rats Hypertension, August 1, 2008; 52(2): 351 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
A L Markel, O E Redina, M A Gilinsky, G M Dymshits, E V Kalashnikova, Y. V Khvorostova, L A Fedoseeva, and G S Jacobson Neuroendocrine profiling in inherited stress-induced arterial hypertension rat strain with stress-sensitive arterial hypertension J. Endocrinol., December 1, 2007; 195(3): 439 - 450. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Manni, A. Holmang, S. Cajander, T. Lundeberg, L. Aloe, and E. Stener-Victorin Effect of anti-NGF on ovarian expression of {alpha}1- and beta2-adrenoceptors, TrkA, p75NTR, and tyrosine hydroxylase in rats with steroid-induced polycystic ovaries Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R826 - R835. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Debrus, L. Rahbani, M. Marttila, B. Delorme, P. Paradis, and M. Nemer The Zinc Finger-Only Protein Zfp260 Is a Novel Cardiac Regulator and a Nuclear Effector of {alpha}1-Adrenergic Signaling Mol. Cell. Biol., October 1, 2005; 25(19): 8669 - 8682. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Veerasingham, M. Yamazato, K. H. Berecek, J. M. Wyss, and M. K. Raizada Increased PI3-Kinase in Presympathetic Brain Areas of the Spontaneously Hypertensive Rat Circ. Res., February 18, 2005; 96(3): 277 - 279. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Lonergan, A. G. Teschemacher, D. Y. Hwang, K.-S. Kim, A. E. Pickering, and S. Kasparov Targeting brain stem centers of cardiovascular control using adenoviral vectors: impact of promoters on transgene expression Physiol Genomics, January 20, 2005; 20(2): 165 - 172. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. B. J. Kuo, C. J. Lai, F.-Z. Shaw, C.-W. Lai, and C. C. H. Yang Sleep-related sympathovagal imbalance in SHR Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H1170 - H1176. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Hao, M. Du, A. Lopez-Campistrous, and C. Fernandez-Patron Agonist-Induced Activation of Matrix Metalloproteinase-7 Promotes Vasoconstriction Through the Epidermal Growth Factor-Receptor Pathway Circ. Res., January 9, 2004; 94(1): 68 - 76. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |